Who are the most active digital health VCs?

This blog post has been written by the person who has mapped the digital health market in a clean and beautiful presentation

Digital health funding reached $25.1 billion globally in 2024, with AI-powered companies capturing 60% of Q1 2025 investments.

Andreessen Horowitz emerged as the most active investor with 26 deals, while mega-rounds above $100 million dominated 51% of funding volumes. The landscape shifted dramatically toward artificial intelligence solutions, creating new opportunities for entrepreneurs targeting clinical documentation, drug discovery, and chronic care management.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Who are the most active digital health VCs in 2024-2025, and what specific companies have they backed?

Andreessen Horowitz leads digital health investment activity with 26 U.S. deals completed in 2024, focusing heavily on AI-enabled healthcare solutions and growth-stage companies.

General Catalyst ranks second with 25 digital health deals, including major investments in Infinitus ($52 million) and the unicorn-creating Truveta round ($320 million in Series C). Their portfolio emphasizes platforms demonstrating clear return on investment for healthcare payers.

Flare Capital completed 16 digital health deals in 2024, maintaining its position as a dedicated healthcare technology investor with deep domain expertise. The firm targets companies addressing specific clinical workflows and demonstrating measurable patient outcomes.

Other highly active investors include Alumni Ventures, Khosla Ventures, Bessemer Venture Partners, and Oak HC/FT, each participating in multiple significant rounds throughout 2024. ARCH Venture Partners led the largest deal of the period with Xaira Therapeutics' $1 billion Series A, while Thrive Capital backed Isomorphic Labs' $600 million strategic round in March 2025.

How much has each of these VCs invested in digital health startups, and in how many deals over the last 18 months?

Digital health companies raised $10.1 billion across 497 deals in the U.S. during 2024, with an average deal size of $20.4 million reflecting investor preference for proven business models.

Andreessen Horowitz deployed an estimated $400-500 million across their 26 deals, including their leadership of Formation Bio's $375 million Series D round. Their investment strategy targets companies with validated AI applications and demonstrated clinical impact.

General Catalyst's 25 deals represent approximately $300-400 million in total deployment, with significant participation in growth-stage rounds averaging $15-20 million per investment. Their focus remains on platforms achieving product-market fit with measurable ROI for healthcare stakeholders.

European investors like V Health Investors, Index Ventures, and Nina Capital collectively deployed over $3.3 billion in 2024, benefiting from a 27% year-over-year funding increase. This represents the fastest regional growth globally, creating opportunities for cross-border investment strategies.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Which digital health startups raised the largest rounds recently, and which VCs participated?

Xaira Therapeutics secured the largest funding round with $1.0 billion in Series A funding led by ARCH Venture Partners and Foresite Labs in April 2024, targeting AI-powered drug discovery platforms.

Isomorphic Labs raised $600 million in strategic funding led by Thrive Capital in March 2025, positioning the Alphabet spinout as a leader in AI-driven pharmaceutical research. Formation Bio completed a $375 million Series D led by Andreessen Horowitz, focusing on clinical trial optimization and data analytics.

Truveta raised $320 million in Series C funding in January 2025, achieving unicorn status with its health data analytics platform that serves major health systems. Abridge secured $250-300 million across Series D and E rounds, reaching a $2.8 billion valuation for its AI-powered clinical documentation platform.

These mega-deals ($100M+) dominated the funding landscape, accounting for 51% of Q1 2025 global digital health funding with 15 deals totaling $2.5 billion. This concentration indicates investor preference for mature platforms with demonstrated clinical impact and scalability potential.

What types of technologies or R&D breakthroughs in digital health are attracting the most VC funding right now?

Artificial intelligence applications captured 60% of Q1 2025 digital health funding, up from 37% in 2024, with clinical documentation, drug discovery, and diagnostic imaging leading investment categories.

AI-powered clinical documentation platforms like Abridge represent the fastest-growing segment, automating medical note-taking and reducing physician administrative burden by 2-3 hours daily. Drug discovery AI platforms including Isomorphic Labs and Xaira Therapeutics attract mega-round funding due to their potential to reduce pharmaceutical development timelines from 10-15 years to 5-7 years.

Digital biomarkers and continuous monitoring technologies receive significant investment, enabling real-time health tracking and early disease detection. Longevity and preventive care platforms demonstrate strong consumer willingness to pay, with Function Health achieving nearly 50,000 paying members and companies like Superpower raising $30 million for personalized health testing.

Mental health and chronic care management continue attracting substantial funding, particularly platforms demonstrating 2:1 ROI for employers and payers within the first year. These solutions address the $4 trillion annual healthcare cost burden through prevention and early intervention strategies.

What geographies are most digital health investments focused on—US, Europe, Asia, or elsewhere?

The United States maintains dominant market position with $17.2 billion (70%) of global digital health funding in 2024, hosting 21 of 26 mega deals in H1 2024.

Europe emerged as the surprise growth leader with 27% year-over-year funding increase in 2024, reaching approximately $3.3 billion total investment. Germany, UK, and Nordic countries drive European activity, with London-based startups particularly attractive to U.S. investors seeking geographic diversification.

Asia-Pacific experienced a 19% decline to $2 billion across 244 deals, primarily due to regulatory uncertainty in China and reduced cross-border investment. However, Singapore, Indonesia, and Philippines continue attracting substantial investments, particularly in telemedicine and chronic care management platforms.

This geographic distribution creates arbitrage opportunities for investors willing to back European or Southeast Asian companies at lower valuations before they expand to U.S. markets. European companies typically trade at 30-40% discounts to comparable U.S. valuations despite similar growth metrics and clinical outcomes.

Which digital health companies funded in the past 12 months are already showing traction or product-market fit?

Function Health demonstrates exceptional product-market fit with nearly 50,000 paying members and over 200,000 on the waitlist for comprehensive health testing, achieving $500+ annual revenue per customer.

Hinge Health successfully completed its IPO in May 2025, serving over 4 million members with its AI-powered musculoskeletal care platform and demonstrating 73% symptom improvement rates. Maven Clinic reports 73% of users track their health regularly with 45% reviewing data daily, indicating strong engagement in women's health services.

Parsley Health shows 85% of patients achieving symptom relief and delivers 2:1 ROI for employer clients within the first year, validating its functional medicine approach. These companies demonstrate the key traction metrics investors seek: high user engagement, measurable health outcomes, and positive unit economics.

Truveta achieved unicorn status by serving major health systems with real-world data analytics, processing health records for over 100 million patients. Their platform enables clinical research acceleration and drug development optimization, creating multiple revenue streams from pharmaceutical and research partnerships.

If you want to build or invest on this market, you can download our latest market pitch deck here

Are big tech or pharma companies backing these startups directly or indirectly through CVC arms or partnerships?

Corporate venture capital activity increased significantly, with CVCs participating in 26% of deals in Q1 2023, up from 20% in 2022, driven by strategic innovation and competitive positioning needs.

What stage are the most active digital health investors typically getting involved—pre-seed, Series A, growth?

Early-stage investments dominate by deal count with 86% of labeled funding rounds in 2024 going to startups raising seed, Series A, or Series B rounds, though growth and late-stage rounds capture larger funding amounts.

Series A median deal sizes reached $6.4 million in Q1 2025, up from $5.4 million in 2024, reflecting increased investor confidence in proven business models. Pre-seed and seed funding remains active for AI-enabled startups with strong technical teams and validated use cases, typically ranging from $500K to $3 million.

Late-stage funding showed signs of recovery in Q1 2025, with median deal sizes for Series D rounds reaching $105 million. Growth-stage investors like General Catalyst and Andreessen Horowitz target companies with $10+ million ARR and demonstrated clinical outcomes, writing checks between $20-50 million.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

The stage distribution reflects risk-adjusted return expectations, with early-stage investors seeking 10-20x returns over 5-7 years, while growth investors target 3-5x returns over 3-5 years through proven revenue scaling and market expansion strategies.

What are typical deal sizes, valuation ranges, and ownership stakes for top VCs in this space?

AI-powered digital health companies command premium valuations ranging 2-5x higher than non-AI counterparts, with top-tier platforms achieving 30-50x EV/ARR multiples.

Series A rounds typically range from $5-15 million at $20-40 million pre-money valuations, with lead investors taking 15-25% ownership stakes. Series B rounds average $15-30 million at $50-100 million pre-money valuations, while Series C rounds often exceed $50 million at $200-500 million valuations for companies demonstrating clear path to $100+ million ARR.

Mega-deals above $100 million target companies with proven business models, typically requiring $50+ million ARR and demonstrated clinical outcomes. These rounds often involve multiple investors contributing $25-75 million each, limiting individual ownership dilution while providing substantial growth capital.

Down-round IPOs became more acceptable for companies valued during the 2020-2021 peak, with Hinge Health IPO valued at approximately half its 2021 private valuation. This recalibration creates opportunities for investors to acquire stakes in proven companies at more reasonable valuations before public market recovery.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What are some examples of successful exits (IPOs or acquisitions) in digital health in the past two years?

Hinge Health completed the most significant IPO in May 2025, raising $437.3 million at $32 per share and closing up 17% on its first trading day, serving over 4 million members with AI-powered musculoskeletal care.

M&A remains the primary exit route, accounting for 86% of digital health exits since 2020, with notable recent acquisitions including CentralReach for $1.7 billion in March 2025, Accolade for $621 million in January 2025, and SomaLogic for $350 million in January 2025.

The digital health IPO market expects rebound in 2025 despite recent volatility, with 2024 seeing 6 digital health IPOs globally. These exits validate investor thesis around scalable healthcare technology platforms with demonstrated clinical outcomes and positive unit economics.

Exit valuations reflect multiple compression from 2020-2021 peaks, creating realistic expectations for entrepreneurs and investors while still delivering strong returns for companies achieving $50+ million ARR with sustainable growth rates above 40% annually.

How much total VC capital has been raised and deployed in digital health in 2024 and so far in 2025?

Global digital health funding reached $25.1 billion in 2024, with Q1 2025 adding another $6.3 billion, indicating sustained investor interest despite broader market challenges.

The United States contributed $17.2 billion (70%) of global funding in 2024, while Europe experienced 27% growth to approximately $3.3 billion. Asia-Pacific declined 19% to $2 billion, primarily due to regulatory uncertainty in China and reduced cross-border investment activity.

Mega-deals above $100 million accounted for 51% of Q1 2025 funding with 15 deals totaling $2.5 billion, demonstrating investor preference for proven platforms with demonstrated scalability. This concentration suggests the market is maturing toward fewer, larger investments in companies with validated business models.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Total venture capital deployment is expected to exceed $30 billion annually by 2026, driven by AI adoption, regulatory clarity, and proven ROI models across the healthcare ecosystem.

Based on current trends, what areas of digital health are expected to attract the most VC interest in 2026?

AI-powered healthcare solutions will drive majority investment growth, with the AI healthcare market projected to reach $208.2 billion by 2030, creating substantial opportunities for early-stage investors.

Longevity and preventive care represent emerging high-growth categories, with consumer willingness to pay for proactive health solutions driving investment in companies like Function Health and Superpower. These platforms target the $4.1 trillion wellness market through personalized health optimization and early disease detection.

Regulatory tailwinds including new FDA AI/ML guidance are expected to reduce perceived risks and encourage further investment in AI-powered healthcare solutions. Clinical documentation platforms, diagnostic imaging AI, and drug discovery engines benefit most from regulatory clarity and reimbursement pathway development.

The global digital health market is projected to reach $456.9 billion by 2026 with annual growth rates of 18.8%. Europe is expected to maintain strong growth momentum through increased government healthcare digitization initiatives, while Asia-Pacific recovery depends on regulatory improvements and cross-border investment resumption.

Conclusion

Sources

1. Galen Growth - AI and TechBio Funding Lead the Charge
2. Galen Growth - U.S. Digital Health Funding 2024
3. AHA Center for Health Innovation - Digital Health Funding Surges Q1
4. Accretive Edge - Digital Health Investors 2025
5. Fierce Healthcare - Digital Health Venture Funding Hit $10.1B
6. Visible VC - Venture Capital in Healthcare
7. Vestbee - Top Health Tech VC Funds Investing in Europe
8. Healthcare Brew - Digital Health VC Funding Evolved 2024
9. Galen Growth - Q1 2025 Digital Health Funding Trends
10. Healthcare Dive - Digital Health Funding Declines 2024
11. MedTech Dive - Digital Health Funding Q1 2025
12. Galen Growth - Mega Deals in Digital Health
13. Galen Growth - H1 2024 Digital Health Funding
14. SiliconANGLE - Isomorphic Labs Raises $600M
15. MobiHealth News - Isomorphic Labs Secures $600M
16. MedCity News - Digital Health Funding Bouncing Back
17. LinkedIn - Healthcare AI Unicorn Class H1 2025
18. TechCrunch - 7 New Tech Unicorns 2025
19. Healthcare Digital - Healthcare AI Unicorn Class
20. CB Insights - Digital Health Trends 2024
21. 7wire Ventures - Future of Longevity
22. Fierce Healthcare - Superpower Scores $30M
23. Reuters - Hinge Health Raises $437.3M IPO